Cargando…

Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis

BACKGROUND: Dose fractionation of a coronavirus disease 2019 (COVID-19) vaccine could effectively accelerate global vaccine coverage, while supporting evidence of efficacy, immunogenicity, and safety are unavailable, especially with emerging variants. METHODS: We systematically reviewed clinical tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Bingyi, Huang, Xiaotong, Gao, Huizhi, Leung, Nancy H., Tsang, Tim K., Cowling, Benjamin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595080/ https://www.ncbi.nlm.nih.gov/pubmed/36284331 http://dx.doi.org/10.1186/s12916-022-02600-0

Ejemplares similares

The effect of variation of individual infectiousness on SARS-CoV-2 transmission in households
por: Tsang, Tim K, et al.
Publicado: (2023)

Revisiting assumptions in test-negative studies for estimating vaccine effectiveness: the need for a clinical case definition
por: Sullivan, Sheena, et al.
Publicado: (2023)

Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India
por: Du, Zhanwei, et al.
Publicado: (2022)

Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases
por: Tonacio, Adriana Coracini, et al.
Publicado: (2021)

Vaccination Against SARS-CoV-2 in Lung Transplant Recipients: Immunogenicity, Efficacy and Safety
por: Svorcova, Monika, et al.
Publicado: (2022)

Immunogenicity of Fractional Dose Inactivated Poliovirus Vaccine in India
por: Ahmad, Mohammad, et al.
Publicado: (2021)

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis
por: Anderson, Evan, et al.
Publicado: (2022)

Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
por: Syversen, Silje W., et al.
Publicado: (2022)

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
por: Zhan, Haoting, et al.
Publicado: (2023)

Association Between Population-Level Factors and Household Secondary Attack Rate of SARS-CoV-2: A Systematic Review and Meta-analysis
por: Wang, Can, et al.
Publicado: (2022)

The need for a clinical case definition in test-negative design studies estimating vaccine effectiveness
por: Sullivan, Sheena G., et al.
Publicado: (2023)

Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine
por: Chaiwarith, Romanee, et al.
Publicado: (2023)

CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
por: Jin, Lairun, et al.
Publicado: (2022)

Efficacy, Safety and Immunogenicity of Anti-SARS-CoV-2 Vaccines in Patients with Cirrhosis: A Narrative Review
por: Toutoudaki, Konstantina, et al.
Publicado: (2023)

Safety and immunogenicity of fifth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series
por: Teles, Mayan S, et al.
Publicado: (2022)

Immunogenicity and safety of two-dose SARS-CoV-2 vaccination via different platforms in kidney transplantation recipients
por: Chen, Chien-Chia, et al.
Publicado: (2022)

Risk for International Importations of Variant SARS-CoV-2 Originating in the United Kingdom
por: Du, Zhanwei, et al.
Publicado: (2021)

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
por: Kandeil, Ahmed, et al.
Publicado: (2021)

Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2
por: Almansour, Iman, et al.
Publicado: (2021)

Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial
por: Juan-Giner, Aitana, et al.
Publicado: (2021)

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
por: Lim, Wey Wen, et al.
Publicado: (2021)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine
por: Zeng, Guangting
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer
por: Li, Tong, et al.
Publicado: (2022)

Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents
por: Áñez, Germán, et al.
Publicado: (2023)

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys
por: Zhou, Jun, et al.
Publicado: (2005)

The Effect of Age and Recent Influenza Vaccination History on the Immunogenicity and Efficacy of 2009–10 Seasonal Trivalent Inactivated Influenza Vaccination in Children
por: Ng, Sophia, et al.
Publicado: (2013)

Epidemiology of SARS-CoV-2 Omicron BA.5 Infections, Macau, June–July 2022
por: Xiong, Weijia, et al.
Publicado: (2023)

Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine
por: Grandi, Alberto, et al.
Publicado: (2023)

Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine
por: Grandi, Alberto, et al.
Publicado: (2023)

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients
por: Chevallier, Patrice, et al.
Publicado: (2021)

Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients
por: Kimura, Muneyoshi, et al.
Publicado: (2022)

Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose
por: Pereira, Rosa M.R., et al.
Publicado: (2022)

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
por: Han, Shanshan, et al.
Publicado: (2023)

Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity
por: Shanmugaraj, Balamurugan, et al.
Publicado: (2022)

Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults
por: DiazGranados, Carlos A., et al.
Publicado: (2016)

Association between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity
por: Ng, Ho Yu, et al.
Publicado: (2023)

Using secondary cases to characterize the severity of an emerging or re-emerging infection
por: Tsang, Tim K., et al.
Publicado: (2021)

Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease
por: Cossiga, Valentina, et al.
Publicado: (2023)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
por: Anderson, Evan J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_04l1p8l161m1qmfijbtbn46m0k